Borosil Scientific share price today

Borosil Scientific Ltd's share price was ₹106.34 at the close on 4 November 2026. It has been falling for 5 weeks. That is 17.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹101 and ₹169, and at that close it sat 8% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Borosil Scientific Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 15 weeks running.

Over the last 2.4 years the share price moved −32% while the NIFTY 500 moved +0%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 24 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

2. Revenue up on a year earlier for 5 quarters in a row

   In the September 2026 quarter revenue was ₹115 crore, +7.5% on a year earlier.

3. Profit up on a year earlier for 4 quarters in a row

   In the September 2026 quarter profit was ₹5 crore, +86.6% on a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), Borosil Scientific reported revenue of ₹115 crore, up 7.5% from ₹107 crore a year earlier, and a profit of ₹5.30 crore, up 86.6% from ₹2.84 crore.

Borosil Scientific results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Borosil Scientific closed at ₹106.34 on 4 November 2026, down 20.0% from ₹132.98 a year earlier (7 November 2025). Its highest weekly close since June 2024 was ₹213.95 on 28 June 2024.

Borosil Scientific share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

130 weekly closes from 7 June 2024 to 4 November 2026.

4 Nov 2026: Borosil Scientific closed at ₹106.34, up 4.5% on the week and down 5.7% on the month. Results for July to September 2026: Revenue up 7.5% and profit up 86.6% on a year earlier.

Borosil Scientific has paid no dividend on the NSE since its first NSE close in our records (7 June 2024), the start of the period we checked.

No. Borosil Scientific Ltd paid out 0% of its profit as dividends in each of its last 3 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

Borosil Scientific's management made 0 promises we could check against what it later reported.

Our read after the latest results, written 14 June 2026.

Borosil Scientific is not on any of our India lists this week.

Borosil Scientific Ltd earned ₹5.3 Cr of net profit in the Sep 2026 quarter, +86.6% on the same quarter a year earlier. Full-year FY26 profit was ₹35.0 Cr. Over 2 years profit has grown 23.4% a year on average. That is 4.6% of the quarter's revenue. The same quarter a year earlier earned ₹2.8 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹35.0 Cr (+29.6% on the year before).

Why profit moved: revenue changed +7.5% on a year earlier and the margin moved +1.8 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +135.3% and revenue +12.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Borosil Scientific Ltd reported ₹115 Cr of revenue in the Sep 2026 quarter, +7.5% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 2 years it has grown 8.6% a year on average. The last full year, FY26, came in at ₹462 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Pharma Packaging (glass vials, ampoules) contributed ₹70.3Cr in FY26, FDA/GMP certified facility serving Indian pharma exports. Global pharma packaging market growing at ~6% CAGR. 'China Plus One' supply chain shift creates tailwinds as Indian pharma manufacturers prefer domestic glass packaging. Anti-dumping probes on Chinese borosilicate glass (C016) could tighten import competition.

The last four reported quarters add to ₹486 Cr.

FY26 revenue was ₹462 Cr, +6.5% on the year before.

Recent pace: the last four quarters grew +12.2% on average, against 8.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +12.1%, against +7.3% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +295.5%, against +25.4% a year (accelerating).

Borosil Scientific Ltd's operating margin was 9.3% in the Sep 2026 quarter, 1.8 percentage points higher than the same quarter a year ago. Across 3 years it has been between 12.0% and 14.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Scientific glass manufacturing has high fixed costs (furnace, energy, skilled labor). Revenue grew 21% YoY in Q4 FY26 (₹143Cr vs ₹118Cr implied) while OPM expanded from 13% to 22%, classic fixed-cost leverage. As revenue scales toward ₹550-600Cr over FY27-FY28, the 13% mid-cycle OPM should structurally improve toward 15-16%.

Why the margin moved: operating margin changed +1.8 percentage points on the year while gross margin changed +1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 227% of Borosil Scientific Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹43.0 Cr of operating cash against ₹35.0 Cr of profit. After ₹29.0 Cr of spending on assets, ₹14.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 227% of profit came in as cash: the cash cycle stayed about the same between FY24 and FY26, so the cash follows profit, not the cycle.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Borosil Scientific Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 193 days in FY26, down from 200 days in FY24. It spent ₹42.0 Cr on assets over the last 2 years. Customers take 60 days to pay, and stock sits for 226 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹462 Cr, each day of that cycle ties up about ₹1.3 Cr, so roughly ₹244 Cr is tied up in the business at any time.

FY26: customers took 60 days to pay and stock sat for 226 days, about 7.4 months of sales sitting as stock, for a full cycle of 193 days, shorter than FY24's 200.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 226 days. Customers pay about 60 days after that. Suppliers are paid at 93 days. Together that makes the 193-day cycle.

Spending on assets: ₹42.0 Cr over the last 2 years, against ₹37.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹9.0 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Borosil Scientific Ltd's P/E is 20.1×, about the lowest it has ever been. Its usual P/E (the middle reading) is 49.2×, over 2.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹5.13.

Why the multiple is where it is: over the past year earnings per share moved +29.2% while the price moved −20.0%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Worked out from its price on 20 July 2026, Borosil Scientific Ltd's share price assumed profit growth of about 24.5% a year. Over the past 2 years its profit actually grew 23.4% a year. Today its P/E is 20.1×, lower than 99% of its own last 2.4 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 20 July 2026. Every other number on this page, the multiple included, uses the latest price as of 4 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Borosil Scientific Ltd's business is turning around. Profit growth has swung from −42.1% at its low to +295.5%, improving for 3 quarters in a row, with ROCE falling at 7.0%. This is based on 9 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Borosil Scientific Ltd's story is not scored yet against the checks our research set on 14 June 2026. Where it sits in its own cycle: Not stated in the research file. Still open: Chinese import competition

NOT YET CHECKED

What is proven. See the research file

What is not proven yet. Chinese import competition

The test written in advance. Chinese import competition. Measured by: Chinese import competition Anti-dumping duty imposed → risk reduces. Duty rejected or no action → reassess structural pricing power thesis. by the next result.

The test written in advance. Q4 FY26 PAT spike driven by tax one-off. Measured by: Q4 FY26 PAT spike driven by tax one-off Q1 FY27 PAT sustains ≥₹15Cr on organic margin recovery → confirms underlying earnings power. by the next result.

What the surface reading misses. Here, Q4 FY26 PAT includes an ₹8Cr one-off tax benefit (C009). Still at or below the 10y median of 52.3x. The 0th percentile (33.8x on headline EPS) is partly a statistical artefact of the one-off-inflated FY26 EPS.

What the surface reading misses. The surface reading is: OPM highly volatile (5-22% range), quality concern, business has low earnings visibility The research reads it further: The volatility pattern shows clear seasonality: Q4 (Mar) is consistently the strongest quarter (Mar2024=15.8%, Mar2025=12.8%, Mar2026=22.4%), Q1 (Jun) is weakest (Jun2024=9.4%, Jun2025=5.1%). This is operating deleverage on the seasonally softer quarter, not structural margin erosion. The trend within each fiscal year is recovery from trough.

• 1 · Operating leveragebuilding
• 2 · Value-added mixquiet
• 3 · Management changequiet
• 4 · Paying down debtquiet
• 5 · Regulatory approvalquiet
• 6 · Order-book winsquiet
• 7 · Consolidationquiet
• 8 · Demerger or value unlockquiet
• 9 · Buybackquiet
• 10 · New geographiesquiet
• 11 · More business from existing customersquiet
• 12 · New product launchquiet
• 13 · Mandatory normsquiet
• 14 · A bigger market to servequiet
• 15 · Market-share gainsquiet
• 16 · Asset qualityquiet

Lever 1 · Operating leverage: building. Scientific glass manufacturing has high fixed costs (furnace, energy, skilled labor). Revenue grew 21% YoY in Q4 FY26 (₹143Cr vs ₹118Cr implied) while OPM expanded from 13% to 22%, classic fixed-cost leverage. As revenue scales toward ₹550-600Cr over FY27-FY28, the 13% mid-cycle OPM should structurally improve toward 15-16%. What proves it keeps working: Operating leverage on fixed-cost lab glass manufacturing. It stops working if Anti-dumping duty imposed → risk reduces. Duty rejected or no action → reassess structural pricing power thesis.

Sources: our stock research file (14 June 2026) · quarterly results through Sep 2026. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

Borosil Scientific Ltd earned a ROCE of 12% in FY26. Its return on capital used (ROIC) is 0.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 7.6% net margin and 0.86× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 7.6% net margin × 0.86× asset turnover × 1.22× leverage (assets divided by equity) ≈ 8.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 12.8% − 12.0% = +0.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

The 12.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 11.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Borosil Scientific Ltd has total debt of ₹6.0 Cr against shareholder equity of ₹452 Cr as of Sep 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.49 in FY23 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

No group of Borosil Scientific Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.3 points over the same period, to 0.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: +0.4 points over 8 quarters, to 68.3%; Domestic institutions: +0.3 points over 8 quarters, to 0.3%; Foreign institutions: −0.2 points over 8 quarters, to 0.1%.

For Borosil Scientific Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

59.9 out of 100, rank 3 of 6 in Glass & Glass Products, with 78% of the evidence available.

Borosil Scientific Ltd scores 59.9 out of 100 against the 6 companies it is compared with in Glass & Glass Products, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 26.6 + 9.8 + 15.3 + 8.2 = 59.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Borosil Scientific ranks 3 of 6 Glass & Glass Products companies on the 4-Factor Sector Score, with 59.9 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Glass & Glass Products, all 6 compared on one page.

Borosil Scientific is the 5th largest of 6 Glass & Glass Products companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Asahi India Glass, Borosil Renewables, Sejal Glass and Saint-Gobain Sekurit India. Just below it: Empire Industries.

Glass & Glass Products companies close in size

1. Asahi India Glass Ltd ₹26,024 crore
2. Borosil Renewables Ltd ₹6,087 crore
3. Sejal Glass Ltd ₹1,008 crore
4. Saint-Gobain Sekurit India Ltd ₹927 crore
5. Borosil Scientific Ltd ₹905 crore
6. Empire Industries Ltd ₹562 crore

All 6 Glass & Glass Products companies, largest first

Companies close in size in other industries

1661. Vinsys IT Services India Ltd ₹914 crore · Computer Education
1662. Solarworld Energy Solutions Ltd ₹911 crore · Solar EPC
1663. Borosil Scientific Ltd ₹905 crore
1664. Dam Capital Advisors Ltd ₹905 crore · Finance - Investment Bankers
1665. Dhampur Bio Organics Ltd ₹903 crore · Sugar

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.